找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Drug Discovery in Japan; Investigating the So Sadao Nagaoka Book 2019 Springer Nature Singapore Pte Ltd. 2019 Drug discovery.breakthrough.u

[復(fù)制鏈接]
樓主: Halcyon
11#
發(fā)表于 2025-3-23 12:15:40 | 只看該作者
12#
發(fā)表于 2025-3-23 16:43:30 | 只看該作者
Freud, the Subconscious and Virginia Woolf Pharmaceutical. Compared to earlier antihypertensive drugs, candesartan had a new mechanism of action, fewer side effects, and demonstrated efficacy even at low doses. The research project started as exploratory research on diuretics. Takeda discovered CV-2198, the first nonpeptidic ARB, by making
13#
發(fā)表于 2025-3-23 20:46:59 | 只看該作者
https://doi.org/10.1007/978-94-007-5748-6apan. It is also the first antibody drug developed in Japan. Chugai Pharmaceuticals started the basic research on autoimmune disease early, when neither a target molecule nor a disease mechanism was known. The research and development program was long and uncertain, taking 24?years to acquire the ap
14#
發(fā)表于 2025-3-24 01:48:04 | 只看該作者
https://doi.org/10.1007/978-94-007-6149-0. The new gene (PD-1), its function, and the possibility that its suppression can be used to block cancer growth were identified in the laboratory of Prof. Tasuku Honjo at Kyoto University, starting from a serendipitous basic science discovery. Despite concrete demonstrations by Honjo’s team of the
15#
發(fā)表于 2025-3-24 03:48:18 | 只看該作者
16#
發(fā)表于 2025-3-24 10:30:48 | 只看該作者
https://doi.org/10.1007/978-981-13-8906-1Drug discovery; breakthrough; uncertainty; delegated initiative; competition; Statin; Opdivo
17#
發(fā)表于 2025-3-24 10:52:01 | 只看該作者
18#
發(fā)表于 2025-3-24 15:15:12 | 只看該作者
19#
發(fā)表于 2025-3-24 20:11:53 | 只看該作者
20#
發(fā)表于 2025-3-25 00:35:26 | 只看該作者
often incomplete when discovery starts, requiring sustained .This book analyzes the drug-discovery process in Japan, based on detailed case studies of 12 groups of 15 innovative drugs. It covers the first statin in the world up to the recent major breakthrough in cancer therapy, the recent immune ch
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經(jīng)驗總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-9 09:55
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
修武县| 安宁市| 龙山县| 民和| 遂平县| 巴马| 英德市| 梁山县| 文安县| 库伦旗| 雷山县| 昌乐县| 吉安县| 涞源县| 嵩明县| 彰化市| 寻乌县| 田林县| 敖汉旗| 洮南市| 秭归县| 云龙县| 离岛区| 无锡市| 增城市| 渝北区| 岗巴县| 靖远县| 漠河县| 自治县| 文昌市| 南漳县| 海阳市| 镇康县| 镇原县| 大城县| 同德县| 于田县| 长治县| 辽阳市| 襄垣县|